Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Epidiolex | cannabidiol | Dravet Syndrome (DS) | Active | |||
| Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Active | |||
| Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Epclusa | Sofosbuvir/ velpatasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entyvio | Vedolizumab | Ulcerative colitis | List with clinical criteria and/or conditions | Complete | ||
| Entyvio | Vedolizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entuzity KwikPen | human insulin | Diabetes mellitus | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entresto | sacubitril/valsartan | Heart failure, NYHA Class II or III | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024